Floatz logo

Egfrbi-Armed Autologous Activated T Cells

Malignant Tumor of Colon

Barbara Ann Karmanos Cancer InstituteCell therapyPhase 1Dormant
C
32/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
95/ 100

Competitive context

158 Active assets in the Malignant Tumor of Colon cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Akeso
Phase 4A
Irinotecan
Fudan University
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Akeso
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

Egfrbi-Armed Autologous Activated T Cells is also rated in:

pancreatic neoplasmDormant
C
Indicative ·
32 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
32 / 100
View asset →
Colon CarcinomaDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →